Abstract
The Clinical Response and Efficacy Study of Bortezomib in the Treatment of Relapsing Multiple Myeloma (CREST) demonstrated substantial activity with two dose levels of bortezomib (1.0 and 1.3 mg/m(2)), alone or with dexamethasone, in relapsed or refractory multiple myeloma. We present updated survival analyses after prolonged follow-up (median >5 years). One- and 5-year survival rates were 82% and 32%, respectively, in the 1.0 mg/m(2) group (n = 28), and 81% and 45%, respectively, in the 1.3 mg/m(2) group (n = 26). Notable survival, response, and time-to-progression data suggest that a bortezomib starting dose of 1.3 mg/m(2) is preferred. If bortezomib dose reduction is required, the 1.0 mg/m(2) dose still offers patients a substantial survival benefit.
Publication types
-
Clinical Trial, Phase II
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Boronic Acids / administration & dosage
-
Boronic Acids / therapeutic use*
-
Bortezomib
-
Dexamethasone / administration & dosage
-
Disease Progression
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Epidemiologic Methods
-
Female
-
Follow-Up Studies
-
Humans
-
Male
-
Middle Aged
-
Multiple Myeloma / drug therapy*
-
Pyrazines / administration & dosage
-
Pyrazines / therapeutic use*
-
Recurrence
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Boronic Acids
-
Pyrazines
-
Bortezomib
-
Dexamethasone